Multivessel Disease (MVD): 60 Second Insights
Published: 08 March 2018
57sPart 1 | Session 1 Keith Oldroyd Keith G Oldroyd
1m 7sPart 1 | Session 2 Simon Walsh Simon J Walsh
1m 8sPart 1 | Session 3 Paul Knaapen Paul Knaapen
53sPart 1 | Session 4 Colin Berry Colin Berry
51sPart 2 | Session 1 Keith Oldroyd Keith G Oldroyd
57sPart 2 | Session 2 Simon Walsh Simon J Walsh
A short series of 60-second insight videos on Multivessel Disease (MVD).
More from this programme
How do manage patients with multi-vessel disease during PPCI?
Do you think we should be doing multi-vessel revascularisation instead of CABG? If so, in which cases?
Do you prefer Clopidogrel, Ticagrelor or Prasugrel?
Do you have any concerns giving adenosine during PPCI or would your prefer and adenosine-free technique?
Do you believe registry (i.e. culprit only) or RCT data (treat all vessels)?
Do you believe coronary physiology has a role in non-culprit PPCI decision-making?
Are you using G2B3A inhibitors like ReoPro?
Are you using Bivalirudin or Heparin?
What trials best support the use of MVD PCI?
Should we balloon acutely and then returning to stent the following morning?
Interventional Cardiologist and Professor
Dr Paul Knaapen is an Interventional Cardiologist, the Director of Cardiac PET/CT and a Professor of Interventional Cardiology at Amsterdam UMC, Netherlands. 4
Dr Knaapen received his M.D. from the VU University School of Medicine. He then completed his internship, residency and interventional cardiology fellowship at the VU University Medical Center.5
Dr Knaapen is Professor of Cardiac Intervention and Imaging, Division of Cardiology at the VU University Medical Center, where his major research interest is the clinical value of non‐invasive cardiac imaging, with a particular focus on hybrid PET/CT and chronic total occlusions (CTOs).5
As a clinical researcher, he has co-authored 223 peer-reviewed articles and participated in 7…